Lee Ainslie Cassava Sciences Inc Transaction History
Maverick Capital LTD
- $5.84 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
962KPut Options Held
864K-
Black Rock Inc. New York, NY3.22MShares$14.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$9.81 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny984KShares$4.45 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$3.57 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$2.77 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $181M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...